Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Effect of CT1812 Treatment on Brain Synaptic Density

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03493282
Recruitment Status : Completed
First Posted : April 10, 2018
Last Update Posted : January 12, 2022
Information provided by (Responsible Party):
Cognition Therapeutics

Brief Summary:
This is a single-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812, administered for up 180 days for the Primary study and another 180 days for the Double blind extension study.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: Active Treatment- CT1812 100 mg Drug: Placebo Drug: Active Treatment- CT1812 300 mg Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease
Actual Study Start Date : March 28, 2018
Actual Primary Completion Date : October 16, 2020
Actual Study Completion Date : October 16, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Active Treatment- CT1812 100 mg
7 subjects randomized to 100 mg CT1812
Drug: Active Treatment- CT1812 100 mg
Active Study Drug
Other Name: Study Drug

Active Comparator: Active Treatment- CT1812 300 mg
7 subjects randomized to 300 mg CT1812
Drug: Active Treatment- CT1812 300 mg
Active Study Drug
Other Name: Study Drug

Placebo Comparator: Placebo
7 subjects randomized to matching placebo
Drug: Placebo
Non-active study drug
Other Name: Matching placebo

Primary Outcome Measures :
  1. Number of study participants with treatment related adverse events and serious adverse events. [ Time Frame: Up to 30 weeks ]
    To evaluate the safety of CT1812 in AD patients by assessing by TEAEs and SAEs

  2. Changes in brain synaptic density over a six month period using the SV2A PET ligand 11C-UCB-J. [ Time Frame: Up to 30 weeks ]
    Evaluating the effect of CT1812 on brain synaptic density over 30 week time period in Alzheimer's disease (AD) patients using the SV2A PET ligand 11C-UCB-J

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants may be included in the study only if they meet all of the following criteria:

    1. Men, and women of non-childbearing potential, 50-85 years of age inclusively, with a diagnosis of mild to moderate Alzheimer's disease according to the 2011 NIA-AA criteria and at least a 6 month decline in cognitive function documented in the medical record.

      1. Non-childbearing potential for women is defined as postmenopausal [last natural menses greater than 24 months; in women under age 55, menopausal status will be documented with serum follicle stimulating hormone (FSH) test] or undergone a documented bilateral tubal ligation or hysterectomy.
      2. Male participants who are sexually active with a woman of child-bearing potential must agree to use condoms during the trial and for 3 months after last dose unless the woman is using an acceptable means of birth control. Acceptable forms of birth control include abstinence, birth control pills, or any double combination of: intrauterine device (IUD), male or female condom, diaphragm, sponge, and cervical cap.
    2. Neuroimaging (MRI) obtained during screening consistent with the clinical diagnosis of Alzheimer's disease and without findings of significant exclusionary abnormalities (see exclusion criteria, number 3).
    3. MMSE 18-26 inclusive
    4. A positive amyloid (Pittsburgh imaging compound B) scan at screening, or history of a positive amyloid scan prior to study entry, or prior lumbar puncture with a CSF Abeta concentration consistent with Alzheimer's disease.
    5. Formal education of eight or more years.
    6. Must have a caregiver who sees them at least 10 hours per week, oversees the administration of study drug, and is willing and able to oversee administration of study medication and participate in all clinic visits and some study assessments. The caregiver must provide written informed consent to participate in the study.
    7. Living at home or in the community (assisted living acceptable)
    8. Able to swallow CT1812 capsules.
    9. Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening.
    10. Capable of providing either written informed consent or oral assent to the study procedures and for use of protected health information [Health Insurance Portability and Accountability Act (HIPAA) Authorization, if applicable]. If the Participant can provide only assent, their legally authorized representative also must provide written informed consent. Written informed consent also shall be obtained from the responsible caregiver. All consent processes must be undertaken in the presence of a witness and prior to any study procedures.
    11. Must consent to apolipoprotein E (ApoE) genotyping.
    12. Generally healthy with mobility (ambulatory or ambulatory-aided, i.e., walker or cane), vision and hearing (hearing aid permissible) sufficient for compliance with testing procedures.
    13. Able to complete all screening evaluations.

Exclusion Criteria:

  • Participants will be excluded from the study if any of the following conditions apply:

    1. Hospitalization or change of chronic concomitant medication within one month prior to screening.
    2. Patients living in a continuous care nursing facility
    3. Screening MRI of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct > 1 cm3, >3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g. abscess or brain tumor such as meningioma).
    4. MRI incompatible implants and other contraindications for MRI, such as pacemaker, artificial joints, non-removable body piercings, etc. Additionally, participants who meet the following imaging exclusion criteria will not be included in this study:

      1. Claustrophobia that will result in significant anxiety and difficulty lying still for brain imaging (MRI or PET).
      2. Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the participant to exceed the yearly dose limits for healthy volunteers.
      3. History of IV drug use that would prevent venous access for PET tracer injection.
      4. Severe motor problems that prevent the participant from lying still for brain imaging.
      5. Severe chronic pain (e.g., as the result of rheumatoid arthritis) that would prevent them from lying still during brain imaging.
    5. Clinical or laboratory findings consistent with:

      1. Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Jacob-Creutzfeld Disease, Down's syndrome, etc.)
      2. Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral sclerosis, etc.)
      3. Seizure disorder
      4. Other infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, other laboratory values) etc.)
    6. A current DSM-V diagnosis of active major depression, schizophrenia or bipolar disorder. Patients with depressive symptoms successfully managed by a stable dose of an antidepressant are allowed entry.
    7. Clinically significant, advanced or unstable disease that may interfere with outcome evaluations, such as:

      1. Chronic liver disease, liver function test abnormalities or other signs of hepatic insufficiency (ALT, AST, total bilirubin > 1.5 x ULN)
      2. Respiratory insufficiency
      3. Renal insufficiency eGFR < 45 mL/min based on the CKD-EPI formula ( disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within six months before screening)
      4. Bradycardia (<45/min.) or tachycardia (>100/min.)
      5. Poorly managed hypertension (systolic >160 mm Hg and/or diastolic >95 mm Hg) or hypotension (systolic <90 mm Hg and/or diastolic <60 mm Hg)
      6. Uncontrolled diabetes defined by HbA1c >8
    8. History of cancer within 3 years of screening with the exception of fully excised non-melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 6 months.
    9. Seropositive for human immunodeficiency virus (HIV).
    10. History of acute/chronic hepatitis B or C and/or carriers of hepatitis B (seropositive for Hepatitis B surface antigen [HbsAg] or anti-Hepatitis C [HCV] antibody).
    11. Clinically significant abnormalities in screening laboratory tests, including:

      1. hematocrit less than 33% for males and less than 30% for females
      2. absolute neutrophil cell count of 1200/uL (with the exception of a documented history of a chronic benign neutropenia), or platelet cell count of < 120,000/uL
      3. INR >1.4 or other coagulopathy, confirmed by repeat.
    12. Disability that may prevent the patient from completing all study requirements (e.g. blindness, deafness, severe language difficulty, etc.)
    13. Women who are fertile and of childbearing potential.
    14. Within 4 weeks of screening visit or during the course of the study, concurrent treatment with antipsychotic agents (except risperidone ≤1.5 mg/day, quetiapine ≤100 mg/day, olanzapine ≤5 mg/day, and aripiprazole ≤10 mg/day), antiepileptics (except gabapentin and pregabalin for nonseizure indications), centrally active anti-hypertensive drugs (e.g., clonidine, l-methyl dopa, guanidine, guanfacine, etc.), opiate analgesics, systemic corticosteroids, psychostimulants, antiparkinsonian medications (except for non-parkinsonian indications) and mood stabilizers (e.g., valproate, lithium), sedatives and anxiolytics with the exception that use of short- to medium-acting benzodiazepines for treatment of insomnia is permitted, however, use of sedatives or hypnotics should be avoided for 8 hours before administration of cognitive tests.
    15. Any disorder that could interfere with the absorption, distribution, metabolism or excretion of drugs (e.g. small bowel disease, Crohn's disease, celiac disease, or liver disease.)
    16. Nootropic drugs except stable AD meds (acetylcholinesterase inhibitors and memantine
    17. Suspected or known drug or alcohol abuse, i.e. more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day indicated by elevated MCV significantly above normal value at screening.
    18. Suspected or known allergy to any components of the study treatments.
    19. Enrollment in another investigational study or intake of investigational drug within the previous 30 days or five half-lives of the investigational drug, whichever is longer.
    20. Previous exposure to anti Aβ vaccines
    21. Exposure to passive immunotherapies for AD (e.g. monoclonal antibodies) or BACE inhibitors within the previous 180 days.
    22. Contraindication to undergoing an LP including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; international normalized ratio (INR) > 1.4 or other coagulopathy; platelet count of < 120,000/μL; infection at the desired lumbar puncture site; taking anti-coagulant medication within 90 days of screening (Note: low dose aspirin is permitted); degenerative arthritis of the lumbar spine; suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma.
    23. Use of NSAIDs more than 2 days in within any 7-day period. Each incidence of use must be recorded in the source and CRF.
    24. Any condition, which in the opinion of the investigator or the sponsor makes the patient unsuitable for inclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03493282

Layout table for location information
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
Sponsors and Collaborators
Cognition Therapeutics
Layout table for investigator information
Principal Investigator: Christopher van Dyck, MD Yale University
Layout table for additonal information
Responsible Party: Cognition Therapeutics Identifier: NCT03493282    
Other Study ID Numbers: COG0105
First Posted: April 10, 2018    Key Record Dates
Last Update Posted: January 12, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders